Pfizer Inc. / Baxter International Inc. (commercial vaccines portfolio)

Meningococcal C Disease and Tick-Borne Encephalitis Prophylaxis

$300M Combined NeisVac-C + FSME-IMMUN/TicoVac annual sales at deal time

Disease Overview

Meningococcal disease is a rapidly progressing bacterial infection caused by Neisseria meningitidis with mortality of approximately 10-15% even with treatment; serogroup C historically caused major outbreaks in Europe before conjugate vaccine programs. Tick-borne encephalitis is a flavivirus infection transmitted by ixodid ticks across endemic zones in Central/Eastern Europe, Russia, and parts of Asia, producing meningoencephalitis with risk of permanent neurologic sequelae. Both are vaccine-preventable.

Competitive Landscape

At the time of the July 2014 announcement, the meningococcal C vaccine space was anchored by Baxter's NeisVac-C (polysaccharide-tetanus toxoid conjugate) competing with GSK's Menjugate and Sanofi's Menactra/MenACWY franchise; Pfizer was simultaneously building MenB capability through Trumenba (FDA approval Oct 2014). Pfizer's Prevnar 13 dominated pneumococcal disease — adding NeisVac-C and the TBE vaccine FSME-IMMUN/TicoVac let Pfizer broaden into adjacent serious infectious disease prophylaxis, especially in European markets where NeisVac-C and FSME-IMMUN had strong shelf positions and where TBE was the only commercially available prophylaxis (the parallel Western competitor was GSK/Novartis's Encepur). Combined annual sales were ~$300M; Pfizer paid $635M cash plus assumed a portion of Baxter's Orth, Austria manufacturing site. Strategically the deal was a bolt-on against Baxter's preparation to spin out Baxalta in 2015. Sentiment among analysts was modestly positive on Pfizer (revenue-accretive) and slightly negative on Baxter (15c per share 2015 EPS dilution, per Zacks).